Impact of high-intensity foundational medical therapy on outcomes across risk profiles in heart failure with reduced ejection fraction
Heart Failure Reviews · 17.11.2026 · 31 (1)
DOI: 10.1007/s10741-026-10697-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart Failure Reviews, online erschienen am 17.11.2026. Verfasst von Snega Rajini Laxmi und 1 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) is a major global health challenge, characterized by high morbidity, mortality, frequent hospitalization, and substantial healthcare costs, despite recent therapeutic advances. In heart failure with reduced ejection fraction (HFrEF; LVEF < 50%), foundational medical therapy (FMT), as defined in the 2026 European Society of Cardiology (ESC) guidelines—comprising renin–angiotensin system inhibition or angiotensin receptor–neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium–glucose cotransporter-2 inhibitors—reduces morbidity and mortality, but its benefit depends on how completely, how quickly, and how intensively these therapies are implemented. This narrative review evaluates whether the benefit of early, comprehensive, high-intensity FMT in HFrEF differs according to specific baseline risk modifiers, drawing on the STRONG-HF trial and its secondary analyses, other randomized evidence, and real-world studies. In STRONG-HF, a high-intensity care strategy that combined rapid up-titration of renin–angiotensin system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists with close post-discharge follow-up reduced the composite of all-cause death or HF readmission at 180 days, driven mainly by fewer HF readmissions; all-cause mortality alone was not significantly reduced, and sodium–glucose cotransporter-2 inhibitors were not part of the protocolized strategy. Secondary analyses found no significant heterogeneity of this effect across MAGGIC risk tertiles or systolic blood pressure strata, whereas associations between higher attained doses and better outcomes were observational. Meta-analyses of randomized trials additionally support early initiation of mineralocorticoid receptor antagonists and sodium–glucose cotransporter-2 inhibitors after decompensation. Prognostic scores, physiological parameters, and treatment-exposure measures are treated as distinct constructs rather than as an interchangeable single risk category. The review also addresses tools for risk prognostication, the boundary between FMT optimization and evaluation for mechanical circulatory support in advanced HF, and the real-world barriers to implementation, including patient comorbidity, therapeutic inertia, health-system constraints, and cost. Available evidence supports early initiation and structured optimization of FMT in appropriately selected HFrEF patients, with no convincing evidence that higher baseline risk alone justifies therapeutic inertia; however, the independent contributions of treatment completeness, dose intensity, and monitoring intensity, the optimal sequencing, and individualized dose targets remain uncertain, particularly in very high-risk and underrepresented populations, and warrant further prospective study.
Zitieren
APA
Laxmi, S. R., & Chellasamy, R. T. (2026). Impact of high-intensity foundational medical therapy on outcomes across risk profiles in heart failure with reduced ejection fraction. Heart Failure Reviews, 31(1). https://doi.org/10.1007/s10741-026-10697-1
Vancouver
Laxmi SR, Chellasamy RT. Impact of high-intensity foundational medical therapy on outcomes across risk profiles in heart failure with reduced ejection fraction. Heart Failure Reviews. 2026;31(1). doi:10.1007/s10741-026-10697-1
BibTeX
@article{Laxmi2026,
author = {Laxmi, Snega Rajini and Chellasamy, Rajeev Thilak},
title = {Impact of high-intensity foundational medical therapy on outcomes across risk profiles in heart failure with reduced ejection fraction},
journal = {Heart Failure Reviews},
year = {2026},
volume = {31},
number = {1},
doi = {10.1007/s10741-026-10697-1}
}
EUVIMED